Obulytix is focused on the development of the next generation enzyme-based antibiotics to address the rapidly expanding antimicrobial resistance crisis. Our inspiration comes from nature by exploiting the power of phage lysins, highly performant enzymes produced by bacteriophages to rapidly kill bacteria. This novel class of antibiotics fulfills all innovation criteria for antibiotics as defined by the World Health Organization (WHO). Our company runs the most advanced development platform for phage lysins, empowered by artificial intelligence (AI), to address the high medical need of new antibiotics targeting multidrug-resistant bacteria.
Reach out to us if you wish to collaborate.
Company Details
- Employees
- 12
- Founded
- -
- Address
- Valentin Vaerwyckweg 1, Gent,oost-Vlaanderen 9000,belgium
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.obulytix.com
- HQ
- Gent, Oost-Vlaanderen
Obulytix Questions
Obulytix's website is http://www.obulytix.com
Obulytix's LinkedIn profile is https://be.linkedin.com/company/obulytix
Obulytix has
12 employees.
View email and phone details for 12
employees at Obulytix.
Obulytix's industry is
Biotechnology Research
Obulytix's top competitors are
Phiogen,
Glox Therapeutics Ltd.,
Smart In Media,
Argenx,
Zymofix,
Adaptive Phage Therapeutics,
Snap Discovery,
Thryve,
Nuclivision,
Amalus Therapeutics.
Obulytix's categories are Biotechnology Research
Obulytix's founding year is 2023
